{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-158320","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2024-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.320068+00:00","generated_at":"2026-06-01T05:21:34.791119+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vor Biopharma CFO Nathan Jorgensen resigns; CEO Ang named interim principal financial officer","bullets":["Nathan Jorgensen resigns as CFO effective June 21, 2024, to pursue a new opportunity; no disagreement cited.","CEO Robert Ang appointed interim principal financial officer; VP of Finance Amy Quinlan interim principal accounting officer.","Company has launched search for a permanent CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-158320","json":"https://secwatch.observer/filing/0001193125-24-158320.json","markdown":"https://secwatch.observer/filing/0001193125-24-158320.md","text":"https://secwatch.observer/filing/0001193125-24-158320.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524158320/0001193125-24-158320-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524158320/d847248d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:21:34.791119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25b2280d6f","claim":"Robert Ang was appointed as Interim Principal Financial Officer at Vor Biopharma Inc..","evidence_excerpt":"On June 8, 2024, the Board designated Robert Ang, M.B.B.S., M.B.A., the Company’s President and Chief Executive Officer and a director of the Company, as the Company’s interim principal financial officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524158320/0001193125-24-158320-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"designated"},{"label":"Role","value":"Interim Principal Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"7482551cc3","claim":"Amy Quinlan was appointed as Interim Principal Accounting Officer at Vor Biopharma Inc..","evidence_excerpt":"and Amy Quinlan, the Company’s Vice President of Finance, as the Company’s interim principal accounting officer, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524158320/0001193125-24-158320-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"designated"},{"label":"Role","value":"Interim Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"cd4406822c","claim":"Nathan Jorgensen resigned as Chief Financial Officer at Vor Biopharma Inc..","evidence_excerpt":"On June 4, 2024, Nathan Jorgensen, Ph.D., M.B.A., notified Vor Biopharma Inc. (the “Company”) of his resignation as Chief Financial Officer of the Company, effective as of June 21, 2024 (the “Effective Date”), in order to pursue a new opportunity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524158320/0001193125-24-158320-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}